Our Vision

Contributing to people’s health based on Science and Innovation
Since 2004, we have been working with pharmaceutical companies and academia to analyze the functions of genes in various cells that form the basis of the human body and mechanism by which proteins are expressed.
The development of new drugs and therapeutics requires a long development period and high R&D costs. In cellular research, the basic research stage, we aim to contribute to leaps forward in new drug discovery by providing more reliable and efficient technologies and services.
Innovation and improvement in life sciences are rapid, but are supported by strenuous research efforts.
Based on our accumulated core technology, we will develop applications and supply products and services leading to the improvement of medical world and meeting customer’s needs.
To that end, we will continue to develop and improve our technology.
We will strive to establish a sustainable business so that we can realize our objectives.

Message from CEO

I am Ryuji Yamamoto , CEO of CytoPathfinder, Inc.
While I did not have previous experience in life sciences, in 2010, by request of government officials, I started to support CytoPathfinder, a bio-venture with unique technology, spun out from the National Insitute.
Utilizing my long experience establishing and managing small and medium size enterprises, together with our staff,we will focus on only one product type worldwide.
Small but having a big dream, we are aiming, together with business partners globally, to solve customers’ problems and meet their expectations.

Ryuji Yamamoto
CEO,CytoPathfinder,Inc.

Business

Transfection experiments are important tools in in vitro high-throughput loss-of-function assays in drug discovery and medical research, and are conducted in academic research institutes and pharmaceutical companies worldwide.
The transfection experiments themselves are conventionally conducted in the liquid phase.
In our solid-phase method, various nucleic acids, transfection reagents and our patented accelerator are dried as a non-covalently bound complex on the bottom surface of SBS standard micro plates.
We are providing these solid-phase transfection plates to customers.
This allows customers to simply add cells and apply their existing liquid handling & assay system no additional systems are required.
We are ready to consult with customers at both the planning and data analysis stages of their experiments.
We have been providing high density multi-well palates (1536,384,96 well) for high –throughput screening.
In addition, we are developing large volume solid -phase cell culture plate to support cell therapy approaches.

Company Information

Company Name CytoPathfinder, Inc.
Established December 20, 2004
Capital JPY 17.65 Million
End of Fiscal Year November
Management Team · Ryuji Yamamoto(CEO)
· Alun McCarthy, Ph.D. (CSO)
· Keiji Mitani
Auditors · Masayoshi Ishikawa
Address JS Ichigaya Building 6F, 5-1 Gobancho, Chiyoda-ku, Tokyo 102-0076, Japan
Phone +81-3-3264-0780



History

Dec. 2004 Established as spin –out venture company of the National Institute of Science and Technology (AIST)
2008 Licensed out of our siRNA solid –phase transfection technology to Takeda Pharmaceutical; (in-company use)
2009 CytoPathfinder acquired PGIS Ltd. and its wholly-owned UK subsidiary PGXIS Ltd., a pharmacogenomic specialist company.
2010 FANCL unveils a High Performance Anti-aging Cosmetic Material Co-developed with CytoPathfinder
Mar. 2011 Shareholders and Management team was reorganized, with Mr. Ryuji Yamamoto inducted as President, CEO
2015 All intangible assets of PGXIS, UK acquired by C4X Discovery Ltd, UK, and PGXIS became a sleeping company.
2019 We have started joint work with PhoenixBio Co., Ltd. concerning in vitro siRNA transfection assay kits for human hepatocyteo cells from PXB mice
2021 CytoPathfider Innovation Center moved from AIST Rinkai to Nishi-Shinjuku
2021 Successful crowd-funding using FUNDINNO.

Government subsidy projects

2009-2011 NEDO* grants subsidy to CytoPathfinder for the development of a Cellular Pharmacogenomics (PGx) system for profiling hepatotoxic compounds. (*New Energy and Industrial Technology Development Organization)
2011-2014 CytoPathfinder was a grant recipient in two global technology collaboration support programs for FY2013
“Prototyping and global dissemination of a human iPS cell production plate kit”
2013-2014 “Prototyping and overseas sales channel development of a tool kit for supporting human miRNA functional analytical research”
May 2022 CytoPathfinder grant recipient “Development of large –volume gene edited cell culture plate using
solid-phase transfection technology”

Cooperative research with Academia

2010-. CytoPathfinder begins collaboration with AIST on Cellular PGx. and solid –phase transfection of Plasmid DNA
2014 Study of hepatitis B onset mechanism by Hiroshima University, CytoPathfinder supplied whole-genome solid-phase screening plates
2014 The Institute of Medical Science, University of Tokyo: Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. We supplied siRNA solid –phase transfection screening plates.
2014 Oxford University/ Karolinska Institute Whole –genome siRNAs screening, double knockdown experiment for anti-cancer drug development targeting DNA repair mechanism.
2014-. National Institute of Health Science : Whole genome siRNA screening for the analysis of antisense nucleic acid uptake mechanism
2014-. Tohoku University, Graduate school of Medicine: Development of ER+ Breast cancer Subtype Classification using clinical samples.
We supplied Plasmid DNA solid-phase transfection plate (non viral method was needed)
Aug 2020 Co- research with AIST “Study of assay system and gene analysis using mouse multipotent stem cell
by using solid –phase transfection plates
TOP